Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
electroCore, Inc. is a commercial-stage medical device company focused on non-invasive neuromodulation therapies. The company operates within the medical devices and biotechnology industries, specializing in vagus nerve stimulation (VNS) delivered without surgical implantation. Its core product platform is designed to treat neurological and neuropsychiatric conditions by modulating neural activity through external electrical stimulation.
The company’s primary revenue is driven by sales and licensing of its gammaCore devices, which are FDA-cleared for the acute treatment and prevention of migraine and cluster headache, and for adjunctive use in pain-related indications. electroCore serves patients, healthcare providers, government agencies, and payors, with a unique market position as the first company to commercialize a handheld, non-invasive VNS therapy with multiple regulatory clearances. Founded in 2005, electroCore evolved from early clinical research in bioelectronic medicine to a publicly traded company listed on Nasdaq under the ticker ECOR following its 2018 initial public offering.
Business Operations
electroCore generates revenue primarily through its Neuromodulation Therapy business, which includes device sales, recurring usage-based revenues, and government contracts. The company commercializes its technology through its wholly owned subsidiary electroCore Medical, LLC, which manages U.S. clinical, regulatory, and commercial operations. International sales are conducted through a combination of direct operations and third-party distributors.
The company’s core asset is its proprietary non-invasive VNS technology, which underpins the gammaCore product family. electroCore also maintains long-term research and development programs and has entered into multi-year contracts with the U.S. government, including the Department of Defense and Veterans Affairs, to evaluate and deploy its technology for conditions such as post-traumatic stress disorder, traumatic brain injury, and pain management.
Strategic Position & Investments
electroCore’s strategy centers on expanding indications for its non-invasive VNS platform, increasing reimbursement coverage, and growing adoption in both civilian and military healthcare settings. The company continues to invest in clinical trials, health economics studies, and real-world evidence to support broader regulatory approvals and payor acceptance. Government-funded research and procurement contracts represent a significant strategic pillar, providing non-dilutive capital and validation of its technology.
Rather than pursuing large-scale acquisitions, electroCore has focused on organic growth and targeted investments in clinical development and intellectual property. Its portfolio is concentrated in bioelectronic medicine, with emerging opportunities in inflammatory, neuropsychiatric, and autonomic nervous system-related disorders. Data inconclusive based on available public sources regarding material acquisitions or equity investments in external portfolio companies.
Geographic Footprint
electroCore is headquartered in Basking Ridge, New Jersey, and maintains its primary commercial and administrative operations in the United States. The U.S. represents its largest revenue-generating market, supported by FDA clearances, established reimbursement pathways, and government customers.
Internationally, the company has a presence across Europe and Australia, with commercial activity in markets such as the United Kingdom, Germany, and Italy through distribution partners. These regions contribute to revenue growth and serve as platforms for further international expansion as regulatory approvals and reimbursement frameworks evolve.
Leadership & Governance
electroCore was founded by Dan Goldberger, who continues to shape the company’s strategic vision with a focus on clinically validated, non-invasive therapies that address unmet medical needs. The leadership team emphasizes disciplined capital allocation, evidence-based commercialization, and long-term partnerships with healthcare systems and government agencies.
Key executives include:
- Dan Goldberger – Chief Executive Officer
- Thomas J. Errico – Chief Financial Officer
The company is governed by a board of directors with experience in medical devices, life sciences, and public company oversight, supporting electroCore’s regulatory compliance, strategic planning, and shareholder governance objectives.